News & Events about Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Co. (NASDAQ:ADPT Get Rating) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totalling 4,730,000 shares, a decline of 11.1% from the November 30th total of 5,320,000 shares. Based on an average trading...
Adaptive Biotechnologies Co. (NASDAQ:ADPT Get Rating) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 4,730,000 shares, a decrease of 11.1% from the November 30th total of 5,320,000 shares. Based on an average daily trading...
Thinking about buying stock in HTG Molecular Diagnostics, 180 Life Sciences, Six Flags Entertainment, Under Armour, or Adaptive Biotechnologies? Thinking about buying stock in HTG Molecular Diagnostics, 180 Life Sciences, Six Flags Entertainment, Under Armour, or Adaptive Biotechnologies? PR...
Multiple presentations reinforce clonoSEQs ability to provide valuable insights for treatment surveillance and clinical decision-makingMore than 30 clonoSEQ-related abstracts to be presented at the meeting SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT...
Globe Newswire
2 months ago
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepointsAdaptive now accepts blood samples from DLBCL patients in Streck tubes that stabilize ctDNA SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies ...